GlassScriptPhysician profile
Kaitlin D Hahn
NPI 1972959823
$2,777.53
in general payments reported to CMS, 2019-2025
32 companies · $186 in 2025
The $186 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.23 · 2020: $332 · 2021: $545 · 2022: $576 · 2023: $533 · 2024: $528 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.83 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $335.76 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $315.06 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $310.67 | 2021-2024 | Mounjaro, Jardiance |
| Amgen INC. | $302.78 | 2019-2025 | Evenity, Otezla, Repatha |
| Astellas Pharma US INC | $297.16 | 2023-2025 | Veozah, Myrbetriq |
| Mylan Specialty L.P. | $205.40 | 2020-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.17 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $111.42 | 2019-2025 | |
| Abbvie INC. | $104.01 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $88.16 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $82.74 | 2020-2022 | |
| Dexcom, INC. | $69.76 | 2021-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $42.53 | 2021-2024 | Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $39.24 | 2022-2023 | |
| Gilead Sciences, INC. | $30.07 | 2024 | Epclusa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $29.27 | 2021 | |
| Avanir Pharmaceuticals, INC. | $28.77 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.77 | 2022 | |
| Roche Diagnostics Corporation | $24.52 | 2021 | |
| Organogenesis INC. | $21.99 | 2022 | |
| Abbott Laboratories | $21.51 | 2024 | Proclaim |
| Viatris Specialty LLC | $19.61 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $19.22 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $16.12 | 2022 | |
| Biowound Solutions, INC. | $14.96 | 2025 | Bio-Connekt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.55 | 2019 | |
| Genentech USA, INC. | $13.89 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.05 | 2022 | |
| Esperion Therapeutics, INC. | $12.48 | 2020 | |
| Amarin Pharma, INC. | $12.31 | 2019 | |
| Allergan, INC. | $11.23 | 2020 | |
| Organon LLC | $10.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.